SG Americas Securities LLC Purchases 30,108 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

SG Americas Securities LLC boosted its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 207.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,603 shares of the medical technology company’s stock after purchasing an additional 30,108 shares during the period. SG Americas Securities LLC’s holdings in Alphatec were worth $248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of ATEC. Van ECK Associates Corp boosted its position in Alphatec by 11.8% in the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after buying an additional 1,300 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Alphatec by 8.5% in the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock valued at $229,000 after purchasing an additional 1,304 shares during the period. Bayesian Capital Management LP grew its stake in Alphatec by 5.6% in the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock worth $372,000 after purchasing an additional 1,442 shares in the last quarter. Cetera Advisors LLC grew its stake in Alphatec by 15.6% in the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock worth $175,000 after purchasing an additional 1,720 shares in the last quarter. Finally, Comerica Bank increased its holdings in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 5.5 %

Alphatec stock opened at $5.36 on Tuesday. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34. The business has a fifty day moving average price of $5.83 and a 200-day moving average price of $9.07. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The stock has a market capitalization of $749.78 million, a price-to-earnings ratio of -3.60 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.03). Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The business had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. During the same period in the prior year, the business posted ($0.43) EPS. Alphatec’s revenue was up 24.5% compared to the same quarter last year. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ATEC shares. Wells Fargo & Company cut their price target on Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Piper Sandler lowered their price target on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Morgan Stanley lowered shares of Alphatec from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. Barclays assumed coverage on Alphatec in a report on Monday, July 8th. They set an “overweight” rating and a $19.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Insiders Place Their Bets

In related news, Director David M. Demski purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was acquired at an average price of $5.67 per share, with a total value of $283,500.00. Following the completion of the acquisition, the director now owns 288,441 shares in the company, valued at approximately $1,635,460.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 22.80% of the stock is owned by insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.